The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis

被引:48
|
作者
Masias, Camila [1 ]
Cataland, Spero R. [1 ]
机构
[1] Ohio State Univ, Dept Med, Columbus, OH 43210 USA
关键词
VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; ADAMTS13-SPECIFIC IMMUNE-COMPLEXES; THROMBOCYTOPENIC PURPURA; ENDOTHELIAL-CELLS; PLASMA-EXCHANGE; FACTOR-VIII; ANTI-ADAMTS13; ANTIBODIES; RECOMBINANT ADAMTS13; PROSPECTIVE COHORT;
D O I
10.1182/blood-2018-02-791533
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) is a metalloprotease responsible for cleavage of ultra-large von Willebrand factor (VWF) multimers. Severely deficient activity of the protease can trigger an acute episode of thrombotic thrombocytopenic purpura (TTP). Our understanding of the pathophysiology of TTP has allowed us to grasp the important role of ADAMTS13 in other thrombotic microangiopathies (TMAs) and thrombotic disorders, such as ischemic stroke and coronary artery disease. Through its action on VWF, ADAMTS13 can have prothrombotic and proinflammatory properties, not only when its activity is severely deficient, but also when it is only moderately low. Here, we will discuss the biology of ADAMTS13 and the different assays developed to evaluate its function in the context of TTP, in the acute setting and during follow-up. We will also discuss the latest evidence regarding the role of ADAMTS13 in other TMAs, stroke, and cardiovascular disease. This information will be useful for clinicians not only when evaluating patients who present with microangiopathic hemolytic anemia and thrombocytopenia, but also when making clinical decisions regarding the follow-up of patients with TTP.
引用
收藏
页码:903 / 910
页数:8
相关论文
共 50 条
  • [1] ADAMTS13 in thrombotic microangiopathies
    Remuzzi, G
    Galbusera, M
    Mannucci, PM
    BLOOD, 2002, 100 (10) : 3842 - 3842
  • [2] Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP)
    Shah, Neil
    Rutherford, Cynthia
    Matevosyan, Karen
    Shen, Yu-Min
    Sarode, Ravi
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (04) : 514 - 519
  • [3] The Use of ADAMTS13 Assays in Thrombotic Microangiopathies
    Cataland, Spero
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 687 - 689
  • [4] ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies
    Sarig, Galit
    RAMBAM MAIMONIDES MEDICAL JOURNAL, 2014, 5 (04):
  • [5] PREDICTION OF SEVERE ADAMTS13 DEFICIENCY IN PATIENTS WITH THROMBOTIC MICROANGIOPATHIES
    Martinez Nieto, Jorge
    De La Fuente-Gonzalo, Felix
    Gonzalez Fernandez, Fernando Ataulfo
    Ropero, Paloma
    Villegas, Ana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [6] PREDICTION OF SEVERE ADAMTS13 DEFICIENCY IN PATIENTS WITH THROMBOTIC MICROANGIOPATHIES
    Nieto, J. M.
    De La Fuente-Gonzalo, F.
    Villegas, A.
    Gonzalez, F. A.
    Martin, M. P.
    Trujillo, C.
    Garcia-Paredes, L.
    Saez, M.
    Martinez, R.
    Ropero, P.
    HAEMATOLOGICA, 2015, 100 : 142 - 143
  • [7] Thrombotic Microangiopathies: Role of ADAMTS-13
    Adil, Salman Naseem
    Karim, Farheen
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2012, 62 (02) : 91 - 92
  • [8] Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies
    Mackie, Ian
    Langley, Katy
    Chitolie, Andrew
    Liesner, Ri
    Scully, Marie
    Machin, Samuel
    Peyvandi, Flora
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (03) : 488 - 496
  • [9] ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases
    Rieger, M
    Mannucci, PM
    Hovinga, JAK
    Herzog, A
    Gerstenbauer, G
    Konetschny, C
    Zimmermann, K
    Scharrer, I
    Peyvandi, F
    Galbusera, M
    Remuzzi, G
    Böhm, M
    Plaimauer, B
    Lämmle, B
    Scheiflinger, F
    BLOOD, 2005, 106 (04) : 1262 - 1267
  • [10] Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)
    Rieger, M
    Ferrari, S
    Hovinga, JAK
    Konetschny, C
    Herzog, A
    Koller, L
    Weber, A
    Remuzzi, G
    Dockal, M
    Plaimauer, B
    Scheiflinger, F
    THROMBOSIS AND HAEMOSTASIS, 2006, 95 (02) : 212 - 220